Awakn Life Sciences Expands World's First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral Addictions
- Written by Newsfile
Groundbreaking Psychedelic Study Will Investigate Binge Eating Disorder, Compulsive Sexual Behavior, and Internet Gaming Disorder
Toronto, Ontario--(Newsfile Corp. - January 5, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn), a biotechnology company developing and delivering psychedelic medicines to better treat...